Tags : Research Agreement

Pharma

Spring Bank Signs a Research Agreement with the University of

Shots: Spring Bank enters into a collaboration with the University of Texas Southwestern Medical Center for the evaluation of Spring Bank’s STimulator of INterferon Gene (STING) antagonist compounds in autoimmune disease models Spring Bank will evaluate novel STING antagonist compounds in mouse models of autoimmune and inflammatory diseases to meet the unmet medical need for […]Read More

Biotech

Tmunity Signs an Exclusive Research Agreement with the University of

Shots: Tmunity & University of California enter into an exclusive research agreement for the improvement of TCR therapies for rare diseases including DIPG in pediatric patients. Tmunity will be responsible for development & commercialization of the H3.3K27M TCR therapy The focus of the collaboration is to strengthen Tmunity’s portfolio by developing therapies for diffuse intrinsic […]Read More

Pharma

OncoSec Signs Research Agreement with Duke University School of Medicine

Shots: Duke University to conduct preclinical studies using HER2-plasmid vaccines + TAVOPLUS (IL-12 plasmids) for HER2+ breast cancer. OncoSec to provide its TAVO and APOLLO (new electroporation generator) to Duke University’s to increase DNA-plasmid cellular transfection rates using lower voltage and a longer pulse width  Duke to utilize OncoSec’s TAVO with high-intensity ultrasound tumor ablation […]Read More

Biotech

Astellas Signs a Research and License Agreement with Xencor for

Shots: Xencor to receive an upfront, development, regulatory & commercialization milestones and royalties on sales of product. Astellas to get exclusive WW license to develop and commercialize bispecific mAb for cancer Xencor to utilize its XmAb technology for the development of bispecific Ab candidates against Astellas’ targets & will take care of initial characterization of […]Read More

Biotech

Eisai Signs a Research Agreement with Cerveau Technologies for its

Shots: Eisai & Cerveau Technologies enter into a research collaboration to utilize Cerveau’s [F-18]MK-6240 in PET scan for assessing the status of neurofibrillary tangles (NFTs) in the brain The focus of the collaboration is to utilize Cerveau’s [F-18]MK-6240 as a biomarker and to evaluates its effect in Eisai’s neurodegenerative research studies Cerveau’s MK-6240 is a […]Read More